

# A Novel Application for Murine Double Minute 2 Antagonists

## The p53 Tumor Suppressor Network Also Controls Angiogenesis

Bernd R. Binder

Impairment of the p53 tumor suppressor network<sup>1</sup> is thought to be involved in a large percentage of tumors either by mutations in the *p53* gene<sup>2–4</sup> or by increased expression of its major control system, the MDM2<sup>5</sup> (murine double minute 2; HDM2 for its human equivalent). It is important to realize that levels of p53 are subjected to an autoregulatory feedback loop by MDM2<sup>6,7</sup> as p53 upregulates *MDM2* gene expression and MDM2 protein in turn binds to p53. MDM2 is an E3 ubiquitin ligase and transports p53 to the cytoplasm where it promotes p53 ubiquitination and degradation by the proteasome. In human cancer, increased levels of MDM2<sup>6</sup> are caused either by gene amplification, increased expression induced by activated p53, stabilization by an aberrantly spliced form of HMDX<sup>8</sup>, or augmented translation. In addition to these mechanisms, functional single-nucleotide polymorphisms (SNP) such as the 1 at nucleotide 309 (SNP309) in the *MDM2* gene can modulate MDM2 expression and cause increased tumor progression.<sup>9</sup> Thus, mutations in the *p53* gene or an increase in MDM2 protein impair the effectiveness of p53-dependent proapoptotic and cell-cycle arrest mechanisms and thereby favor the development of tumors. In addition, MDM2 has also p53-independent activities<sup>10,11</sup> through interactions with proteins involved in controlling cell proliferation and survival. This concatenation of data indicated that disruption of the p53–MDM2 autoregulatory feedback loop as well as inhibition of MDM2 would be a suitable strategy for tumor therapy. In fact, Vassilev et al<sup>12</sup> recently developed a class of small molecules, the nutlins (eg, nutlin-3, a tetra-substituted imidazoline), that occupy the p53-binding pocket in MDM2<sup>13</sup> thereby preventing MDM2 binding to p53. Similarly, nutlin-3 also binds to and interferes with MDMX,<sup>14</sup> another component of the p53 tumor surveillance pathway. This leads to a disruption of the autoregulatory feedback loop and consequently the p53 tumor suppressor network is fostered. Consistently, Vassilev et al further showed that nutlin-3 induces apoptosis especially in cancer cell lines with increased

MDM2 expression<sup>15</sup> which correlates well with in vivo antitumor efficacy of nutlin-3 (Figure 1).

An antitumor strategy that interferes with the p53 – MDM2 feedback loop should therefore work best in tumors with wild type p53 (approximately ≈50% of all tumors) and increased MDM2 which suppresses functional active p53. On the other hand, such a strategy does not appear to be promising in tumors with a mutated *p53* gene. In this issue of *Circulation Research*, Secchiero et al,<sup>16</sup> however, report that nutlin-3 may have additional potent antitumor activities by a novel effect of this molecule on angiogenesis. This antiangiogenic effect of nutlin-3 might be an important widening of the possible therapeutic window for nutlin-3 as it is assumed that endothelial cells of blood vessels supplying even a tumor with mutations in p53 do in general not contain such p53 mutations. It is now clear that tumor growth and progression critically depend on an adequate blood supply.<sup>17,18</sup> Moreover, antiangiogenic therapies have the advantage of not inducing tumor resistance. Thus, a nutlin-3 based antitumor therapy might also have potential in tumors containing a mutated and nonfunctioning *p53* gene.

What are the underlying mechanisms for the antiangiogenic activity of nutlin-3? In this article the authors demonstrate that nutlin-3 has antiangiogenic activities via 3 different mechanisms: (1) by inhibiting endothelial cell migration, which seems to be the predominant effect; (2) by inducing cell cycle arrest; and (3) by increasing apoptotic tendency in endothelial cells. The authors also show that nutlin-3 treatment of endothelial cells leads to accumulation of p53, indicating that the effects of nutlin-3 in these cells are also related to its interference with the p53–MDM2 autoregulatory feedback loop (Figure 2). There are only few reports of a direct effect of p53 in endothelial cells.<sup>19</sup> However, with respect to tumor cell migration an effect of p53 on cell

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.


From the Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna.

Correspondence to Bernd R. Binder, Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Schwarzschanerstr. 17, 1090, Austria. E-mail bernd.binder@meduniwien.ac.at


(*Circ Res.* 2007;100:13-14.)

© 2007 American Heart Association, Inc.

*Circulation Research* is available at <http://circres.ahajournals.org>  
DOI: 10.1161/01.RES.0000255897.84337.38



**Figure 1.** The p53–MDM2 autoregulatory feedback loop in cancer (modified according to Harris<sup>24</sup>): nutlin-3 inhibits increased MDM2 activity and thereby restores p53 levels.



**Figure 2.** The p53–MDM2 autoregulatory feedback loop in endothelial cells: nutlin-3 increases normal p53 levels and thereby interferes with normal endothelial cell function.

motility has been demonstrated which is largely mediated through the regulation of Rho signaling, thereby controlling actin cytoskeletal organization (reviewed in<sup>20</sup>). One could speculate that in analogy to tumor cells a similar mechanism might be responsible for the effects in endothelial cells.

The data presented here by Secchiero et al are far from clinical applications and even the *in vivo* data are restricted to a Matrigel plug system in mice. Nevertheless, these data might open a new route for a broader application of nutlin-3 or other MDM2 antagonists<sup>7,21,22</sup> not only for direct antitumor therapies but also for application in antiangiogenic regimens.<sup>23</sup>

### Source of Funding

Supported partially by the EU 6th framework program EVGN (contract number LSHM-CT-2003–503254) and the EU 6th Framework Integrated Project Cancerdegradome (LSHC-CT-2003–503297).

### Disclosures

None.

### References

1. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. *Nature*. 2004;432:307–315.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. *Science*. 1991;253:49–53.
3. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. *Adv Cancer Res*. 2000;77:81–137.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature*. 2000;408:307–310.
5. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. *Nucleic Acids Res*. 1998;26:3453–3459.
6. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. *Curr Cancer Drug Targets*. 2005;5:3–8.

7. Fischer PM, Lane DP. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? *Trends Pharmacol Sci*. 2004;25:343–346.
8. Giglio S, Mancini F, Gentiletti F, Sparaco G, Felicioni L, Barassi F, Martella C, Prodosmo A, Iacovelli S, Buttitta F, Farsetti A, Soddu S, Marchetti A, Sacchi A, Pontecorvi A, Moretti F. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. *Cancer Res*. 2005;65:9687–9694.
9. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. *Cell*. 2004;119:591–602.
10. Zhang Z, Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. *Curr Cancer Drug Targets*. 2005;5:9–20.
11. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. *Proc Natl Acad Sci U S A*. 1998;95:15608–15612.
12. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. *In vivo* activation of the p53 pathway by small-molecule antagonists of MDM2. *Science*. 2004;303:844–848.
13. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. *Science*. 1996;274:948–953.
14. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA. Inactivation of the p53 pathway in retinoblastoma. *Nature*. 2006;444:61–66.
15. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. *Proc Natl Acad Sci U S A*. 2006;103:1888–1893.
16. Secchiero P, Corallini F, Gonelli A, Dell'eva R, Vitale M, Capitani S, Albini A, Zauli G. Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3. *Circ Res*. 2007;100:61–69.
17. Carmeliet P. Angiogenesis in health and disease. *Nat Med*. 2003;9:653–660.
18. Folkman J. Angiogenesis-dependent diseases. *Semin Oncol*. 2001;28:536–542.
19. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. *Proc Natl Acad Sci U S A*. 2000;97:12782–12787.
20. Roger L, Gadea G, Roux P. Control of cell migration: a tumour suppressor function for p53? *Biol Cell*. 2006;98:141–152.
21. Vassilev LT. p53 Activation by small molecules: application in oncology. *J Med Chem*. 2005;48:4491–4499.
22. Fotouhi N, Graves B. Small molecule inhibitors of p53/MDM2 interaction. *Curr Top Med Chem*. 2005;5:159–165.
23. Zhong X, Li X, Wang G, Zhu Y, Hu G, Zhao J, Neace C, Ding H, Reed E, Li QQ. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. *Int J Oncol*. 2004;25:445–451.
24. Harris CC. Protein-protein interactions for cancer therapy. *Proc Natl Acad Sci U S A*. 2006;103:1659–1660.

KEY WORDS: angiogenesis ■ MDM2 ■ p53 ■ nutlin-3

# Circulation Research

JOURNAL OF THE AMERICAN HEART ASSOCIATION



## A Novel Application for Murine Double Minute 2 Antagonists: The p53 Tumor Suppressor Network Also Controls Angiogenesis

Bernd R. Binder

*Circ Res.* 2007;100:13-14

doi: 10.1161/01.RES.0000255897.84337.38

*Circulation Research* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2007 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circres.ahajournals.org/content/100/1/13>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation Research* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Circulation Research* is online at:  
<http://circres.ahajournals.org/subscriptions/>